Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae
Open Access
- 1 June 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (6), 2278-2279
- https://doi.org/10.1128/aac.01561-06
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Clinical Evaluation of Macrolide-Resistant Mycoplasma pneumoniaeAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human MycoplasmasAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and UreaplasmasAntimicrobial Agents and Chemotherapy, 2003
- Susceptibilities of Mycoplasma hominis, M. pneumoniae , and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and QuinolonesAntimicrobial Agents and Chemotherapy, 2001
- Characteristics of Macrolide‐Resistant Mycoplasma pneumoniae Strains Isolated from Patients and Induced with Erythromycin In VitroMicrobiology and Immunology, 2001
- Macrolide–ketolide inhibition of MLS‐resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNAMolecular Microbiology, 2000
- In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-QuinoloneAntimicrobial Agents and Chemotherapy, 1999
- AzithromycinDrugs, 1998
- Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infectionsJournal of Antimicrobial Chemotherapy, 1997
- Erythromycin resistance by ribosome modificationAntimicrobial Agents and Chemotherapy, 1995